Clinical Trials Logo

Endocarditis, Bacterial clinical trials

View clinical trials related to Endocarditis, Bacterial.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06418048 Recruiting - Clinical trials for Infective Endocarditis

INfectious DIsease REgistry BIObank

INDI-REBIO
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

NCT ID: NCT06403839 Recruiting - Endocarditis Clinical Trials

Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Surgical Valve Replacement Patients

DENSVAR
Start date: January 1, 2020
Phase:
Study type: Observational

In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with surgical valve replacement was changed from mandatory to targeted PDS to from march 2024. The investigators will therefore compare the risk of IE before vs after march 2024.

NCT ID: NCT06330766 Recruiting - Endocarditis Clinical Trials

Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Transcatheter Aortic Valve Implantation Patients

DENTAVI
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with Transcatheter Aortic Valve Implantation (TAVI) was changed from mandatory to targeted PDS to between June 2023 to october 2023. The investigators will therefore compare the risk of IE before june 2023 and after october 2023.

NCT ID: NCT06309680 Recruiting - Clinical trials for Infective Endocarditis

Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients

AMetIP
Start date: April 24, 2023
Phase:
Study type: Observational

Infective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs. We are very keen to improve the treatment of this disease and we are measuring the impact of the treatments that we give to patients so that we have a very clear idea of which treatments work best and also which treatments are less successful. A key part of the treatment is the accurate determination of the causative organism which allows appropriate targeted antibiotic and antifungal medication to be administered. Accurate antibiotic regimes require detection of the causative organism and its sensitivities to each antibiotic. Antibiotic choice is then based on effectiveness, toxicity, ease of use and national guidelines. The current best technique for identifying bacteria is blood culture where organisms are identified by growing them from blood samples. However, this takes up to 5 days from sampling, resulting in delays to the correct diagnosis. Until this time, treatment requires the use of generic, more toxic antibiotic regimes. New techniques are emerging to identify causative organisms from blood. Metagenomics allows the sequencing of bacterial DNA allowing precise identification of the infecting organism.

NCT ID: NCT06250985 Recruiting - Clinical trials for Endocarditis, Bacterial

New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System

POET-PPM
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The goal of this randomized clinical trials is to ascertain the safety and efficacy of immediate reimplantation of cardiac electronic implantable devices in patients with endocarditis and device-infections, compared to standard care, i.e. reimplantation at a later procedure date. The primary outcome is the occurence of the composite primary endpoint within 6 months of randomization consisting of - Death - Symptomatic embolism (systemic arterial embolism or pulmonary embolism) - Bacteremia og pocket-infection - Removal of a CIED due to new infection

NCT ID: NCT05862025 Recruiting - Clinical trials for Infective Endocarditis

Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).

ET-AUREUS
Start date: September 4, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective interventionist cohort study is to assess the prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia at low risk of this complication. The main questions it aims to answer are: - Determine whether the risk of infective endocarditis in patients with Staphylococcus aureus bacteriemia identified as low-risk, using the VIRSTA score, is low enough to safely omit transthoracic or transesophageal echocardiography. - Determine whether the risk of infective endocarditis in patients with Staphylococcus aureus bacteriemia in patients with no identifiable risk factor is low enough to safely omit transthoracic or transesophageal echocardiography. - Calculate a cost-benefit estimate of omitting echocardiographic testing in patients identified as low-risk by means of the above methods. Participants will undergo mandatory transthoracic and transesophageal echocardiography during the first 2 weeks from Staphylococcus aureus bacteremia onset.

NCT ID: NCT05791357 Recruiting - Clinical trials for Endocarditis Infective

The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to prospectively investigate the additional diagnostic value of broad range PCR targeting the 16 ribosomal DNA in diagnosis and management of patients with infective endocarditis who are candidate for surgicaltherapy;

NCT ID: NCT05721781 Recruiting - Bacteremia Clinical Trials

Reducing Risk for Infective Endocarditis

PIE-B
Start date: August 31, 2023
Phase: N/A
Study type: Interventional

This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be prevented with a dental cleaning and more education on how to best brush and care for their teeth. One group of participants will have a dental cleaning and oral health instructions and the other group of participants will not. Researchers will compare the blood test results from the two groups to see if the education made a difference in preventing bacteria and how long it stays in the bloodstream.

NCT ID: NCT05703022 Recruiting - Clinical trials for Heart Valve Diseases

Early Exercise Training in Patients Following Heart Valve Surgery for Infective Endocarditis.

Start date: November 30, 2021
Phase: N/A
Study type: Interventional

A prospective, interventional, single-group, single centre study to evaluate the feasibility of early aerobic exercise training in patients following heart valve surgery for infective endocarditis.

NCT ID: NCT05644990 Recruiting - Clinical trials for Endocarditis, Bacterial

T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis

Start date: September 1, 2022
Phase:
Study type: Observational

Our prospective observational study focuses on the rapid detection of etiologic agents of pyogenic spondylodiscitis and infective endocarditis using the T2 Bacteria Panel (T2Biosystems). This diagnostic method combines polymerase chain reaction (PCR) and T2 magnetic resonance for detection of bacterial DNA from whole blood samples. It detects six pathogens known by the acronym ESKAPE (E. coli, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecium). In recent years, similar studies using the Bacteria Panel and Candida Panel have been performed in patients with bloodstream infections, leaving us with optimistic results.The aim of this study is to verify whether T2B can identify the etiologic agents of localized infections, specifically spondylodiscitis and endocarditis, with better sensitivity and specificity and shorter time to result compared to conventional diagnostics from blood culture. Rapid detection of pathogen may reduce time to targeted pathogen-specific antibiotic therapy and subsequently improve outcomes, shorten the treatment and contribute to slowing the development of antibiotic resistance.